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MaIsolated left ventricular noncompaction (ILVNC) is a cardiomyopathy that was ﬁrst described in 1926 as a “spongy
myocardium.” The disorder results from intrauterine arrest of compaction of the loose interwoven meshwork of the fetal
myocardial primordium and subsequent persistence of deep trabecular recesses in the myocardial wall. The classical
clinical presentation is a triad of heart failure, arrhythmias, and embolic events from mural thrombi. ILVNC has been
associated with several autosomal dominant, X-linked, and mitochondrial genetic mutations that are also shared among
other cardiomyopathies. Over the past decade, ILVNC has been subject to intensive research, as it increases the risk for
sudden cardiac death. This review focuses on the current understanding of ILVNC in adult populations and attempts to
provide organized insight into the disease process, screening, diagnosis, management, role of device therapy, and
prognosis. (J Am Coll Cardiol 2015;66:578–85) © 2015 by the American College of Cardiology Foundation.I solated left ventricular noncompaction (ILVNC)is a rare cardiomyopathy classiﬁed as a primarygenetic cardiomyopathy by the American Heart
Association (1). It is still considered unclassiﬁed in
the European Society of Cardiology classiﬁcation (2),
as it remains unclear whether it represents a distinct
disease process or a morphological trait shared by
many phenotypically different cardiomyopathies.
ILVNC results from intrauterine arrest of compac-
tion of the loose meshwork of the fetal myocardial
primordium (3,4) and subsequent persistence of deep
trabecular recesses in the myocardial wall. The ﬁrst
pathological description of spongy myocardium dates
back to 1926 (5). However, ILVNC was ﬁrst designated
as a clinical entity in 1984, identiﬁed by the isolated
persistence of “sinusoids” in the left ventricle (6),
which communicate with the left ventricular cavity
and are usually ﬁlled with blood from the ventricle.
Note that if noncompaction is concomitantly present
with other structural abnormalities (i.e., hypertrophic
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ILVNC has gained increasing attention (1,2) because
of its association with high rates of mortality and
morbidity in adults, including heart failure, thrombo-
embolic events, and tachyarrhythmias (8). Paradoxi-
cally, its prognosis appears better when identiﬁed
early in childhood (9). This review focuses on the cur-
rent understanding of ILVNC in the adult population
and provides an illustrative portrayal of the disorder.
EMBRYOLOGY
During embryogenesis, the myocardium consists of
a loose network of interwoven ﬁbers separated by
deep intertrabecular recesses linking the myocardium
with the left ventricular cavity. Between the ﬁfth
and eighth weeks of embryonic development, this
meshwork compacts, proceeding from the epicardium
to the endocardium and from the base of the heart to
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AB BR E V I A T I O N S
AND ACRONYM S
CMR = cardiac magnetic
resonance
ICD = implantable
cardioverter-deﬁbrillator
ILVNC = isolated left
ventricular noncompaction
NYHA = New York Heart
iation
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579from intrauterine arrest of this process, due to pres-
sure overload or myocardial ischemia preventing the
normal compaction process and regression of the
myocardial sinusoids (8).
Although noncompaction of the myocardium is
seen in association with other congenital cardiac ab-
normalities (Table 1), it can also occur as a primary
disorder in the absence of other structural heart dis-
ease (7). This latter circumstance, referred to as
ILVNC, is the topic of this review.
PREVALENCE
The true prevalence of ILVNC is difﬁcult to determine
because diagnostic criteria are not standardized.
Most studies addressing this issue are from tertiary
medical centers and performed in populations with
symptoms or abnormal physical examination ﬁndings
and for family screening of patients with the disorder
(8,9,13–15). Therefore, a major limitation is that
available prevalence data are derived from retro-
spective databases fraught with selection biases. In a
report from Switzerland, only 0.014% of patients
undergoing echocardiography between January 1984
and December 1998 were identiﬁed as ILVNC cases
(8). However, in the past decade, increased aware-
ness of the disorder, as well as improvements in
echocardiographic image acquisition and processing,
have led to greater detection. Thus, the Swiss study is
likely to have underestimated disease prevalence.
ILVNC is signiﬁcantly more prevalent within the
heart failure population (16,17), which is not sur-
prising, as heart failure remains its most classical
presentation.TABLE 1 Major Gene Mutations Associated With LVNC and Their Over
Disorder
TAZ-G4.5
Mutation
DTNA
Mutation
Z-Band
Mutation
LVNC   
Ventricular/atrial septal defect 
Arrhythmogenic right ventricular
cardiomyopathy
Dilated cardiomyopathy  
Hypertrophic cardiomyopathy
Other cardiomyopathies*  
Other conduction abnormalities†
Tetralogy of Fallot
Ebstein anomaly
Brugada syndrome
Romano-Ward syndrome
*X-linked infantile cardiomyopathy, X-linked endocardial ﬁbroelastosis, hypoplastic left
ACTC ¼ alpha-cardiac actin (24); CSX ¼ cardiac speciﬁc gene located on 5q (65,66
responsible for release of calcium from sarcoplasmic reticulum via ryanodine receptor (6
sequence located on 1q22 (69); LVNC ¼ left ventricular noncompaction; MYH7 ¼ B-myo
human cardiac sodium channel alpha-subunit gene (70); TAZ-G4.5 ¼ encodes tafazzin l
TNNT2 ¼ cardiac troponin T (24); ZASP ¼ Z-band alternatively spliced PDZ motif-contaGENETICS
ILVNC is a genetically heterogeneous disease
that can be either familial or sporadic. Fa-
milial recurrence appears more commonly in
adults with ILVNC (18) than in children (19)
and may be autosomal dominant, X-linked,
or mitochondrial in origin. The recurrence of
noncompaction phenotypes in families varies
between 18% and 50% (8,20,21). Although
retrospective designs limit their general applicability,
prior studies suggest that a detailed pedigree analysis
of patients presenting with ILVNC is warranted. It is
also generally recommended that asymptomatic rel-
atives of affected individuals be screened using
echocardiography (22).
Table 1 describes the major gene mutations asso-
ciated with LVNC that overlap with other cardiac
disorders. Notably, mutations in the sarcomeric car-
diac beta-myosin heavy chain gene (MYH7), previ-
ously linked with hypertrophic cardiomyopathy,
restrictive cardiomyopathy, and dilated cardiomyop-
athy, have been identiﬁed in 2 families with ILVNC
(23), suggesting potential overlap among cardiomy-
opathy genes (23–35).
Despite the major advances noted earlier, the pre-
cise correlation between genotype and phenotypic
expression in cardiomyopathies is poorly understood.
Available data suggest that, for certain mutations,
noncompaction and hypertrophic, restrictive, and
dilated cardiomyopathies are not clearly distinct en-
tities (26,27). In summary, the currently available
genetic data suggest signiﬁcant genetic heterogeneity
in ILVNC, and the major genetic cause for familial
Assoclap With Other Cardiac Disorders
FKBP12
Mutation
LMNA
Mutations
NKX2.5, TBX5,
CSX Mutations
ACTC, TNNT2,
MYH7 Mutation
SCN5A
Mutation
HCN4
Mutation
     
 

  

 
    




heart syndrome. †Bundle blocks, atrioventricular nodal blocks, tachyarrhythmias, bradyarrhythmias.
); DTNA ¼ alpha-dystrobrevin gene, transition C to T mutation, located on 18q12 (19); FKBP12 ¼
7); HCN4 ¼ hyperpolarization-activated cyclic nucleotide channel 4 (68); LMNA ¼ lamin A/C related
sin heavy chain (23–25); NKX2.5 ¼ homeobox protein located on chromosome 5 (65,66); SCN5A ¼
ocated on Xq28, (18,19,71); TBX5 ¼ T-box transcription factor located on chromosome 12 (65,66);
ining protein on 10q22.2-q23.3 (72).
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580noncompaction remains to be identiﬁed. Genetic
testing has not yet yielded improvements in clinical
management of patients but may provide insight as to
the underpinning of ILVNC.
PRESENTATION
ILVNC is characterized by a wide spectrum of pre-
sentations and variable outcomes (28). It is commonly
discovered through screening of family members of
affected patients during early, nonsymptomatic
stages (28). Among symptomatic patients, the triad
of heart failure, arrhythmias, and embolic events
(3,8,10,11) is the most classical presentation, particu-
larly for patients with reduced left ventricular systolic
function (3,29).
In practice, most ILVNC cases are diagnosed in pa-
tients presenting with unexplained heart failure. The
clinical symptoms are usually related to systolic or
diastolic dysfunction; however, nonspeciﬁc symptoms
and/or arrhythmias may be present initially (8,9,11,13–
15,21,22,28,30). Despite increased awareness, there is
still a signiﬁcant delay in establishing the correct
diagnosis, with a mean time from symptom onset of
w3.5 years, although this is likely to have improved
with recent advances in echocardiography.
In a case series by Chin et al. (11), left ventricular
systolic dysfunction was present in up to 60% of pa-
tients. According to the investigators, subendocardial
hypoperfusion and microcirculatory dysfunction may
serve as the etiology for both systolic ventricular
dysfunction and arrhythmogenesis. Subendocardial
perfusion can be abnormal, despite the absence of
coronary artery disease (11), and is believed to result
from isometric contraction of the endocardium and
myocardium within the deep intertrabecular recesses.
Diastolic dysfunction, likely the result of restricted
ﬁlling due to the numerous, prominent trabeculae, is
ubiquitous in ILVNC (10). Initial presentation of
ILVNC as a restrictive cardiomyopathy has been re-
ported in children (21,31), but not in adults.
In a Swiss cohort that was 74% male, reasons for
referral included heart failure (62%), abnormal echo-
cardiographic ﬁndings (12%), and palpitations (6%)
(8). Presenting symptoms included dyspnea in 79%
(65% New York Heart Association [NYHA] functional
classes I and II, 35% NYHA functional classes III
and IV), chest pain (26%), and atrial ﬁbrillation (26%).
The mean left ventricular ejection fraction was 33%,
and 94% of patients had an abnormal electrocardio-
gram (the most common abnormality was left bundle
branch block, observed in w44%). Although embolic
events were not a reason for referral in this series,
they are a common complication.The largest pediatric series (11,21) reported asso-
ciated facial dysmorphism (prominent forehead,
low-set ears, strabismus, high-arching palate, and
micrognathia) and Wolff-Parkinson-White syndrome.
These are generally not present in adult cases and are
likely explained by differing genetics.
The anatomic distribution of ILVNC in pediatric
patients and adults is similar: most commonly api-
cal, followed by midventricular (midinferior and
midlateral segments) and then basal segments. No
septal involvement was noted in a pediatric cohort
of 15 patients (32), with the number of affected
segments being the strongest predictor of systolic
dysfunction.
Although most noncompaction is believed to be
congenital, Finsterer et al. (33,34) suggested that
ILVNC can be acquired. In their case series, patients
had previously normal echocardiograms. Most had
coexistent neuromuscular disorders and mitochon-
driopathies, similar to the congenital form. There are
also a few case reports of ILVNC resulting from
intense athletic training (35) or as an adaptive
mechanism of an impaired myocardium, such as
ischemic heart disease or trauma (36,37). In a retro-
spective review of acquired noncompaction, the
average detection time from a previously normal
echocardiogram was 3.8 years (38).
DIAGNOSIS
Diagnosis of ILVNC is often delayed due to failed
recognition. The absence of a consensus on absolute
diagnostic criteria is a contributing factor. Resting
electrocardiogram abnormalities are found in most
patients, but ﬁndings are nonspeciﬁc and include
left ventricular hypertrophy, repolarization changes,
inverted T waves, ST-segment changes, axis shifts,
intraventricular conduction abnormalities, and
atrioventricular blocks (3,8,11,21). Arrhythmias are
common, including ventricular tachyarrhythmias,
atrial ﬁbrillation, and paroxysmal supraventricular
tachycardia, all of which can precipitate sudden death
(3,8,11).
Two-dimensional echocardiography with color
Doppler is the study of choice for diagnosis and
follow-up of ILVNC. Proposed echocardiographic
criteria for ILVNC include (7):
 Absence of coexisting cardiac abnormalities;
 Segmental thickening of the left ventricular
myocardial wall, consisting of a thin compacted
epicardial layer and a thickened endocardial layer
with prominent trabeculations and deep recesses;
 Noncompaction to compaction ratio $2 at end-
systole (Central Illustration);
CENTRAL ILLUSTRATION Isolated Noncompaction of the Left Ventricle
in Adults: Compaction Ratio for Diagnosis of ILVNC
Epicardium-to-trabecular-trough thickness is termed compacted myocardium (C), and
trabecular-peak-to-trough thickness is termed noncompacted myocardium (NC).
ILVNC ¼ isolated left ventricular noncompaction.
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581 Predominant localization of pathology in the mid-
lateral, apical, and midinferior regions of the left
ventricle (Figure 1); and
 Color Doppler evidence of deep, perfused inter-
trabecular recesses.
Frischknecht et al. (39) validated these criteria
against idiopathic dilated cardiomyopathy and car-
diomyopathy related to valvular or hypertensive
heart disease. Kohli et al. (40), however, argue that
these criteria may be too sensitive, lacking speciﬁcity
for noncompaction. No consensus exists on their
validity, although the speciﬁcity seems likely to be
greater than using the noncompaction/compaction
ratio alone. Similarly, if segments other than those
mentioned in the diagnostic criteria are involved,
ILVNC is unlikely. Note that the morphological
description of abnormal trabeculae varies depending
on the echocardiography planes and the phase of the
cardiac cycle in which these are obtained (40).
Prominent trabeculations should be recognized as
a common variant of normal hearts; this remains
an important diagnostic consideration and clinical
dilemma. In normal hearts, however, trabeculations
most often course from the free wall to the inter-
ventricular septum, whereas in ILVNC, trabeculations
spare the septum (41). The use of contrast echocar-
diography (42) and Doppler tissue (strain rate) imag-
ing (43) can help to further clarify the diagnosis.
Cardiac magnetic resonance (CMR) imaging is
increasingly used in clinical practice to describe
myocardial morphology and can be extremely useful
in conﬁrming the presence of left ventricular non-
compaction (42,44,45). CMR serves a particularly
important role for patients in whom adequate echo-
cardiographic imaging cannot be obtained (Figure 2).
In this setting, transesophageal echocardiography can
also be performed (46).
Two-dimensional CMR measurements adapted
from echocardiographic criteria are similarly limited.
André et al. (47) noted that between 26% and 70% of
healthy volunteers, depending on age and sex, ful-
ﬁlled the 2-dimensional CMR criteria for a non-
compaction diagnosis. Therefore, 3-dimensional CMR
is deemed more appropriate for developing quanti-
tative diagnostic criteria.
A study by Grothoff et al. (48) sought to establish
quantitative CMR diagnostic criteria with good repro-
ducibility that could differentiate noncompaction
from other cardiomyopathies. The 4 basic criteria
include:
1. Noncompacted LV myocardial mass >25%;
2. Total noncompacted LV myocardial mass index
>15 g/m2;3. Noncompacted/compacted myocardium ratio $3:1
in at least 1 segment (1–3,7–16), excluding the api-
cal segment (17); and
4. Trabeculation in segments 4 to 6 $2:1 (non-
compacted/compacted).
Although late gadolinium enhancement (LGE), a
surrogate marker of myocardial ﬁbrosis, was not
identiﬁed in these patients, in previous studies, it
was associated with the clinical features of non-
compaction, including clinical symptoms, electro-
cardiographic abnormalities, and reduced ejection
fraction (49–51).
FIGURE 1 Echocardiographic Images of Left Ventricular Noncompaction
A B C
Transapical views of the left ventricular apex in (A) a normal heart, (B) left ventricular
noncompaction, and (C) left ventricular noncompaction with use of contrast echocardi-
ography to better delineate the abnormal excess trabeculation (arrows) and inter-
trabecular recesses (arrowheads).
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582Other imaging modalities that have been used for
diagnosis of ILVNC include contrast ventriculography
and computed tomography (52), although echocardi-
ography and CMR appear to be the most helpful in
clinical practice (39,45,53,54).
TREATMENT
In general, the management of patients with ILVNC
remains similar to other cardiomyopathies and in-
cludes appropriate evidence-based heart failure
treatments for left ventricular systolic dysfunction,
appropriate management of arrhythmias, and con-
sideration of oral anticoagulation to prevent mural
thrombus formation. With this approach, there ap-
pears to be no signiﬁcant difference in mortality
comparedwith the other cardiomyopathies. In 1 series,
the 3-year survival in patients with ILVNC was 85%,
compared with 83% in patients with dilated cardio-
myopathy (14). Deaths occurred in patients with
decreased LV ejection fraction, suggesting that mor-
tality likely relates more to left ventricular dysfunc-
tion than to the noncompaction itself (14,55). Timely
initiation of renin-angiotensin-aldosterone inhibitors
and beta-blockers, as well as appropriate device ther-
apy (56,57), may prevent complications and improve
survival, although randomized prospective data are
not available in patients with ILVNC.
Ventricular tachyarrhythmias are a major contrib-
utor to mortality in ILVNC, occurring in more than
20% of patients. The risk of sudden cardiac death
remains a major concern, particularly in patients with
advanced disease, and suggests a major role for pro-
phylactic implantable cardioverter-deﬁbrillator (ICD)
therapy. Kobza et al. (58) found that over a 3-yearfollow-up, appropriate ICD discharge occurred in
25% and 50% of patients in whom a deﬁbrillator was
implanted for primary and secondary prevention,
respectively (58). Supraventricular arrhythmias were
also documented in a substantial number of these
patients. These data should be carefully considered
when deciding on the role for devices and their sub-
sequent programming.
There is little to no data regarding the role of
antiarrhythmic therapy in ILVNC. The current pub-
lished data support early aggressive interventions,
including deﬁbrillator implantation and evaluation
for transplantation, for patients with bundle branch
block, increased left ventricular end-diastolic
diameter, permanent or persistent atrial ﬁbrilla-
tion, or NYHA functional class III or IV symptoms
(8). Yearly Holter monitoring also appears to be
essential in ILVNC to screen for asymptomatic
arrhythmias.
Indications for ICD placement remain similar to
other patients with dilated cardiomyopathy. For
ILVNC speciﬁcally, current guidelines suggest that
ICD therapy may be considered (Class IIb recom-
mendation, Level of Evidence: C) (59). ILVNC patients
presenting with syncope or symptomatic arrhythmias
may beneﬁt from electrophysiological study to assess
for potentially inducible arrhythmias, but there are
no available data to support the effect of ablative
interventions in these patients.
Another important aspect of treatment in ILVNC is
the prevention of embolic complications. This is
particularly true for patients with reduced ejection
fraction (<40%), atrial ﬁbrillation, or a history of
thromboembolic complications. Some investigators
recommend long-term prophylactic anticoagulation
for all patients with ILVNC regardless of whether they
have experienced thromboembolic complications (60)
and irrespective of the degree of left ventricular
dysfunction (3,8). However, anticoagulation should
be approached in these patients with careful weigh-
ing of beneﬁt and risk to identify those who will
beneﬁt most from this strategy.
TRANSPLANTATION
Factors in ILVNC that result in more rapid progression
to transplantation or death include greater non-
compaction/compaction ratios and location of
involvement (greatest risk with apical involvement
and lowest with mainly basal distribution) (61).
Patients with severe heart failure (NYHA func-
tional class IIIB or IV) who have failed maximal
medical/device therapy may be candidates for heart
transplantation. According to Mancini et al. (62),
FIGURE 2 Cardiac Magnetic Resonance Images of Left Ventricular Noncompaction
A B C D
E F G H
Steady-state free precession imaging of left ventricular noncompaction (arrows) (A to D) compared with a normal heart (E to H) in short-axis, 4-chamber,
vertical long-axis, and left ventricular outﬂow tract views, respectively.
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583patients with peak VO2 <10 ml/kg/min, a Seattle
Heart Failure Model 1-year predicted survival
score <80%, or medium/high risk Heart Failure Sur-
vival Score should be listed for transplantation. Due
to poor outcomes with transplantation, patients pre-
senting with cardiogenic shock requiring intravenous
inotropes that cannot be tapered due to hypotension,
end-organ damage, or symptoms should be pallia-
tively managed (62).
PROGNOSIS
ILVNC is associated with considerable morbidity and
mortality. In the Swiss cohort, 35% of the patients
suffered early death, 53% required hospitalization for
congestive heart failure, 41% had ventricular tachy-
arrhythmia, 12% required ICDs, and 12% required
heart transplantation over 44 months of follow-up
(8). The overall 5-year survival without heart trans-
plantation was 58%. The high incidence of thrombo-
embolic events (24%) and ventricular tachycardia
(41%) in patients with impaired left ventricular
function was a major contributor to mortality. In a
prospective study of a sub-Saharan African popula-
tion, sudden cardiac death was the most common
cause of mortality (71.4%) in patients with ILVNC and
heart failure (63).
More recent studies have reported substantially
lower morbidity and mortality. Among 45 patientsreferred to a cardiomyopathy center, survival free of
transplantation was 97% over 4 years of follow-up
(22). In another study, 46-month survival tracked
closely with the presence of symptoms at presenta-
tion (69% vs. 100% when absent) (28).
The prognosis of patients with ILVNC has
improved in recent years through earlier identiﬁca-
tion and application of heart failure medications and
device therapy. Although few outcomes trials exist, in
a recent study utilizing serial echocardiography, beta-
blockers prevented the increase in left ventricular
mass seen in the absence of therapy (64).CONCLUSIONS
ILVNC is a rare cardiomyopathy associated with sig-
niﬁcant morbidity and mortality. It should be
considered in the differential diagnosis of any patient
with unexplained heart failure or arrhythmia. The
classical clinical presentation is the triad of heart
failure, arrhythmias, and embolic events.
Early diagnosis and treatment is associated with
improved outcome, and screening asymptomatic rel-
atives of affected patients via echocardiography ap-
pears important. Although echocardiography and
CMR are the modalities of choice, contrast echocar-
diography, left-ventriculography, and computed to-
mography may also be considered.
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584Speciﬁc therapies have yet to be developed for
ILVNC, and standard therapies available for other
cardiomyopathies may be employed with relative
success. Screening for arrhythmias and appropriate
device implantation appears to be critical, as with
other cardiomyopathies and low ejection fraction
states. There also appears to be an important role for
anticoagulation to prevent thromboembolic events.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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